Enliven Therapeutics jumps after cancer drug shows promise in early trial

Enliven Therapeutics

11/04/2024 15:43

** Shares of drug developer Enliven Therapeutics  ELVN.O 
rise 16.8% to $23.14  
    ** Co says its experimental drug to treat chronic myeloid
leukemia (CML), a type of blood cancer, showed preliminary signs
of efficacy and safety in an early-stage study 
    ** The drug, ELVN-001, targets a specific gene which drives
the cancer in CML patients - ELVN  
     ** ELVN-001 was well tolerated and showed responses in a
heavily pre-treated patient population across a wide dose range
-ELVN
    ** 27 patients had enrolled in the ongoing study -ELVN
    ** Including session gains, stock up ~68% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))